Sugi Predict
/ Targets
/ GLG1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to GLG1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease |
PHASE4 | COMPLETED |
| Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Ambroxol as a Treatment for Parkinson's Disease Dementia |
PHASE2 | UNKNOWN |
| A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis |
PHASE1/PHASE2 | RECRUITING |
| Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders |
PHASE2 | COMPLETED |
| Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy |
PHASE2 | COMPLETED |
| Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia |
PHASE2 | COMPLETED |
| Vaccine Treatment for Surgically Resected Pancreatic Cancer |
PHASE1/PHASE2 | COMPLETED |
| Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Targeting Endoplasmic Reticulum Stress in Human Hypertension |
PHASE1/PHASE2 | RECRUITING |
| The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses |
PHASE2 | COMPLETED |
| Vaccine Treatment for Advanced Non-Small Cell Lung Cancer |
PHASE1/PHASE2 | COMPLETED |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease |
PHASE1 | RECRUITING |
| The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism |
EARLY_PHASE1 | UNKNOWN |
| Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine |
EARLY_PHASE1 | COMPLETED |
| Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation |
nan | UNKNOWN |
| Quantification of GADD34 Expression in RA |
nan | COMPLETED |
| Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) |
nan | WITHDRAWN |
| A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease |
nan | COMPLETED |
| Biomarker Analysis for GBA Associated Parkinson's Disease |
nan | UNKNOWN |
| Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy |
nan | UNKNOWN |
| Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease |
nan | COMPLETED |
| Biomarkers Related to Bone in Pediatric Gaucher Disease |
nan | UNKNOWN |
| Genetic Studies of Lysosomal Storage Disorders |
nan | ENROLLING_BY_INVITATION |
| Assessment of Neurological Manifestations in Gaucher Disease Patients |
nan | UNKNOWN |
| Protein Synthesis in the Brain of Patients With Fragile X Syndrome |
nan | COMPLETED |
| Registry Gangliosidoses |
nan | UNKNOWN |
| Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and Neuroimaging |
nan | NOT_YET_RECRUITING |
| Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease |
nan | ENROLLING_BY_INVITATION |
Related proteins — ESM-2 sequence neighbours (a GLG1 binder may also engage these)